Core Viewpoint - Sino Medical Sciences Technology Inc. reported significant growth in revenue and net profit for the first half of 2025, driven by increased sales in its coronary and neuro-interventional product lines, reflecting the company's strong market position and innovation capabilities [2][3][15]. Company Overview and Financial Indicators - Sino Medical is focused on high-end interventional medical devices, with a comprehensive R&D, production, and operational system established over more than a decade [7][14]. - The company achieved a revenue of CNY 240.48 million in the first half of 2025, a year-on-year increase of 12.53% [2][15]. - The net profit attributable to shareholders reached CNY 13.84 million, marking a substantial increase of 296.54% compared to the same period last year [2][15]. - The company's total assets stood at CNY 1.31 billion, with net assets of CNY 894 million at the end of the reporting period [2][15]. Industry Context - The interventional medical device industry in China is experiencing robust growth, supported by government policies aimed at promoting high-end medical equipment development [5][6]. - The coronary intervention market has matured significantly, with a reported 26.44% increase in coronary intervention cases in 2023, indicating strong demand for innovative treatment options [6]. - The neuro-interventional sector is rapidly developing, with increasing domestic innovation and a growing market for neuro-interventional products [6][8]. Product and Innovation - Sino Medical's product portfolio includes leading coronary drug-eluting stents and neuro-interventional devices, with over 2.45 million units used across nearly 4,000 hospitals [8][14]. - The company has maintained a strong focus on R&D, with a total investment of CNY 77.81 million in the first half of 2025, representing 32.36% of its revenue [15]. - The company holds 145 authorized invention patents globally, reflecting its commitment to innovation and technological advancement [15].

在eLum的实验室里，Quang曾用一个简单实验展示技术突破：Quang左手拿起像精密弹簧一样的密网支 架，右手将杯子中的水倒入支架，倒进去的水没有像我们想像中的从支架中漏出来。Quang又拿起一支 铅笔轻轻碰触支架，这时有水漏出来了。这种特性，让支架既能阻断动脉瘤血流使其萎缩，又不影响周 边细小血管供血。 更关键的是，eLum帮助改进后的AUCURA血流导向密网支架可通过0.017"微导管抵达更深、更小的血 管中，且能100%顺利打开，这一性能同类产品很难做到。 技术优势源于材料与工艺的双重创新。AUCURA采用了新型合金材料，使用赛诺独有的电子涂层接枝 技术和编制技术，拥有全球最小的通过外径，能够在X光下实现全显影，具有更优的支架贴壁及更高效 封闭血管瘤能力，临床应用更加安全。而eLum并未止步于此，目前正针对支架显影不佳的行业通病， 研发全新的合金材料，未来有望让支架显影更好、支撑力更强。 宣武医院神经外科副主任何川在2025东方脑血管病会议上曾评价，该支架为远端动脉瘤提供了更安全到 达、更高效愈合、更可靠防护的解决方案，有望开启动脉瘤密网治疗的远近双轨时代。 从技术到产能的协同，是赛诺医疗快速崛起的关 ...